IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11066396 B1

PDFFull Text
Date of Patent:
Jul. 20, 2021

Filed:

Jun. 19, 2017

3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (hdac6) inhibitors

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Abbas Walji, Lansdale, PA (US);

Richard Berger, Harleysville, PA (US);

Craig A. Stump, Pottstown, PA (US);

Kelly-Ann S. Schlegel, Fleetwood, PA (US);

James J. Mulhearn, Elkins, PA (US);

Thomas J. Greshock, Collegeville, PA (US);

Deping Wang, Furlong, PA (US);

Mark E. Fraley, North Wales, PA (US);

Kristen G. Jones, Oreland, PA (US);

Assignee:

MERCK SHARP & DOHME CORP., Rahway, NJ (US);

Attorneys:

Nicole M. Beeler

John C. Todaro

Primary Examiner:

Deepak R Rao

Int. Cl.
CPC ...
C07D 413/04 (2006.01); C07D 413/10 (2006.01); C07D 413/14 (2006.01); C07D 413/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 471/14 (2006.01); C07D 487/04 (2006.01); C07D 491/048 (2006.01); C07D 491/052 (2006.01); C07D 271/06 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 25/18 (2006.01); A61P 11/06 (2006.01); A61P 3/10 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); C07F 7/08 (2006.01); A61P 37/00 (2006.01); C07D 271/113 (2006.01); A61P 37/02 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
C07D 413/10 (2013.01); A61K 45/06 (2013.01); A61P 3/10 (2018.01); A61P 9/00 (2018.01); A61P 11/06 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); A61P 37/02 (2018.01); C07D 271/06 (2013.01); C07D 271/113 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 471/14 (2013.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 491/052 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07F 7/0807 (2013.01);
Abstract

The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

Find Patent Forward Citations

Loading…